Managing TGCV: Current Treatments and Future Options

While there is currently no “cure” for Triglyceride Deposit Cardiomyovasculopathy (TGCV), your medical team has strategies to manage the condition. Treatment focuses on two goals: supporting your heart’s ability to pump using individualized medical therapies and exploring investigational approaches aimed at the “fuel” problem inside your heart cells ^[1].

Standard Heart Failure and Heart Care

If you have TGCV, your doctor will evaluate you for Guideline-Directed Medical Therapy (GDMT). This is the standard “toolkit” for treating heart failure and includes several classes of medication, such as beta-blockers, ACE inhibitors or ARNIs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors ^[1].

Your exact regimen will be highly individualized based on your heart’s ejection fraction, blood pressure, kidney function, and whether you have fluid congestion. You may also need specific medications to manage arrhythmias or standard cardiovascular risks. Never start, stop, or change the dose of these medications without consulting your treating clinician. While these medications are essential for managing symptoms and protecting the heart muscle, some patients with severe TGCV may still experience worsening symptoms ^[2].

The Challenges of Stents (PCI) in TGCV

If you have severe chest pain or critical blockages, your doctor might discuss Percutaneous Coronary Intervention (PCI), which often involves placing a stent to open a blood vessel. Do not delay emergency PCI if you are having a heart attack. However, treating stable TGCV with stents is more complex for several reasons:

• Diffuse Disease: Because the fat builds up throughout the entire length of the vessel (diffuse disease), a single stent may not adequately solve the problem ^[1].
• Restenosis Risks: Observational data suggests TGCV patients may have a higher risk of restenosis (the vessel narrowing again inside the stent). In one small study of patients on dialysis, the rate of re-narrowing at 12 months was approximately 58% in definite TGCV patients compared to less than 10% in those without the disease ^[3]. Note: This study was small and focused on dialysis patients, so these high numbers may not apply exactly to you, but the heightened risk is recognized by specialists.
• Stentless Options: Because of these risks, some interventional cardiologists occasionally explore “stentless” strategies, such as using drug-coated balloons or cutting balloons ^[4]. These are highly specialized options with limited evidence in TGCV, not established routine replacements for stents.

Heart Transplantation

For patients with severe, life-threatening heart failure that is completely refractory (unresponsive) to all medical therapies, heart transplantation may be considered ^[1].

• Reports show that patients who receive a transplant can do very well, with the new heart remaining functional and free of triglyceride deposits years later ^[2].
• A Notable Limit: A transplant only replaces the heart. If you have Primary TGCV (P-TGCV), the genetic mutation is still present in your other muscles, meaning any skeletal muscle weakness will not be cured by a heart transplant ^[2].

Investigational Treatments: Tricaprin (CNT-01)

Researchers are developing a medical formulation called tricaprin (also known as CNT-01), a specific medium-chain triglyceride, to address the core energy failure in TGCV ^[1].

• How it works: Unlike the long-chain fats your heart cannot burn, medium-chain fats can bypass the “broken” enzyme pathway and enter the heart’s energy producers directly ^[5].
• What the Evidence Shows: In an early Phase IIa clinical trial (a small study of 17 patients to evaluate preliminary efficacy and safety), patients taking tricaprin showed a significant improvement in metabolic markers on their BMIPP scans ^[6]. However, clinical symptoms, such as how far patients could walk, did not significantly improve in this short-term study.
• While some observational registry reports have noted long-term survival associations in patients using tricaprin ^[7], this is not proof that the drug directly causes better survival or heart failure recovery.

Tricaprin/CNT-01 is an investigational orphan drug, meaning its safety and full clinical efficacy are not yet established for general use ^[1][8]. Do not substitute over-the-counter medium-chain triglyceride (MCT) oils or supplements for this investigational therapy without explicit specialist guidance.